Crisanta Cruz-Espindola

Crisanta Cruz-Espindola

Auto-generated profile, based on publicly available information

Crisanta Cruz-Espindola

Departments of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Journal of Veterinary Diagnostic Investigation
Verified
Journal Article
Closed access
KTKamoltip Thungrat
Kamoltip Thungrat
PTPhabpim Thumarat
Phabpim Thumarat
AJAlex L. Jenkins
Alex L. Jenkins
CCCrisanta Cruz-Espindola
Crisanta Cruz-Espindola
Phenobarbital, an anti-seizure medication with a narrow therapeutic window, requires therapeutic drug monitoring (TDM) for safe and effective use. Lipemia is a well-known interferent in turbidimetric immunoassays, yet its impact on phenobarbital quantification compared with high-performance liquid chromatography (HPLC) has not been fully characterized. We evaluated the effect of lipemia on phenobarbital measurement using a particle-enhanced turbidimetric inhibition immunoassay (PETINIA; Dimension Xpand Plus clinical chemistry system, Siemens) versus HPLC. Simulated lipemic plasma was prepared by spiking normal canine plasma with lipid emulsion to achieve predefined lipemia indices. Naturally lipemic TDM samples (index ≥ 4; n = 40) and non-lipemic controls (index ≤ 3, n = 40) were also analyzed. Phenobarbital concentrations were compared before and after lipid reduction by double microcentrifugation using both methods. HPLC performance was stable across all lipemia indices, with consistent retention times (5.0 min), accuracy and precision within acceptance limits, and high linearity ( R ² > 0.999). In contrast, PETINIA had a significant positive bias in lipemic samples, with median bias increasing from 9.1% at index 1 to 100% at index 6. Bias was significantly higher in naturally lipemic samples (median: 74.5%) compared with non‑lipemic controls (1.2%; p < 0.001). PETINIA and HPLC had strong agreement in non-lipemic samples (Passing–Bablok regression, r = 0.99), but poor agreement and proportional positive bias in lipemic samples ( r = 0.16; slope CI [1.01, 1.89]). PETINIA overestimated phenobarbital concentrations in lipemic plasma. Microcentrifugation effectively mitigated lipemic interference and improved agreement with HPLC, supporting the use of microcentrifugation in clinical TDM workflows.

21 October 2026 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
NANicole E. Alleva
Nicole E. Alleva
HHHsuan‐Ping Hong
Hsuan‐Ping Hong
JCJoan Ripley Coates
Joan Ripley Coates
CCChen Chen
Chen Chen
CCCrisanta Cruz‐Espindola
Crisanta Cruz‐Espindola
DBDawn M. Boothe
Dawn M. Boothe